Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes

IF 3 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Clinical Endocrinology Pub Date : 2023-12-21 DOI:10.1111/cen.15010

Jimmy Ho Cheung Mak, David Tak-Wai Lui, Carol Ho-Yi Fong, Chloe Yu-Yan Cheung, Ying Wong, Alan Chun-Hong Lee, Ruby Lai-Chong Hoo, Aimin Xu, Kathryn Choon-Beng Tan, Karen Siu-Ling Lam, Chi-Ho Lee

{"title":"Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes","authors":"Jimmy Ho Cheung Mak, David Tak-Wai Lui, Carol Ho-Yi Fong, Chloe Yu-Yan Cheung, Ying Wong, Alan Chun-Hong Lee, Ruby Lai-Chong Hoo, Aimin Xu, Kathryn Choon-Beng Tan, Karen Siu-Ling Lam, Chi-Ho Lee","doi":"10.1111/cen.15010","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (<i>N</i> = 30) or sitagliptin 100 mg daily (<i>N</i> = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.</p>\n </section>\n \n <section>\n \n <h3> Patients and Measurements</h3>\n \n <p>Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (<i>p</i> = .012), CAP (<i>p</i> = .015) and LS (<i>p</i> = .011) after 24 weeks.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (<i>p</i> = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (<i>r</i> = .487, <i>p</i> = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.</p>\n </section>\n </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15010","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen.15010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Baseline circulating thrombospondin-2 (TSP2) level was identified as a potential novel hepatic fibrosis biomarker that associates with development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease and type 2 diabetes. Here, we investigated whether circulating TSP2 levels changed with improvement in liver stiffness (LS), which reflects liver fibrosis on transient elastography.

Design

Serum TSP2 levels were measured in participants from a randomized, open-label intervention study, at baseline and after 24-weeks treatment of either dapagliflozin 10 mg (N = 30) or sitagliptin 100 mg daily (N = 30). Vibration-controlled transient elastography was performed to evaluate the severity of hepatic fibrosis and steatosis using LS and controlled attenuation parameter (CAP), respectively.

Patients and Measurements

Among all 60 participants with similar clinical characteristics at baseline (mean HbA1c 8.9%, CAP 289 dB/m and LS 5.8 kPa), despite similar HbA1c lowering, treatment with dapagliflozin, but not sitagliptin, led to significant improvements in body weight (BW) (p = .012), CAP (p = .015) and LS (p = .011) after 24 weeks.

Results

Serum TSP2 level decreased significantly from baseline in dapagliflozin-treated participants (p = .035), whereas no significant change was observed with sitagliptin. In correlation analysis, change in serum TSP2 levels only positively correlated with change in LS (r = .487, p = .006), but not with changes in BW, CAP or HbA1c after dapagliflozin treatment.

Conclusions

Serum TSP2 level decreased with LS after dapagliflozin treatment, and was independent of improvements in BW, glycemic control and hepatic steatosis, further supporting the potential of serum TSP2 level as a novel hepatic fibrosis biomarker in type 2 diabetes.

Abstract Image

查看原文本刊更多论文

血清凝血酶原-2 水平随 2 型糖尿病患者肝硬变改善而变化。

目的循环中凝血酶原-2（TSP2）的基线水平被认为是一种潜在的新型肝纤维化生物标志物，它与非酒精性脂肪肝和2型糖尿病患者肝纤维化的发生和发展有关。在此，我们研究了循环 TSP2 水平是否会随着肝脏僵硬度（LS）的改善而发生变化：设计：一项随机、开放标签干预研究的参与者在基线和每天服用达帕格列净 10 毫克（30 人）或西他列汀 100 毫克（30 人）24 周后测量血清 TSP2 水平。进行振动控制瞬态弹性成像，分别使用LS和控制衰减参数（CAP）评估肝纤维化和脂肪变性的严重程度：在基线临床特征相似（平均 HbA1c 8.9%、CAP 289 dB/m 和 LS 5.8 kPa）的所有 60 名参与者中，尽管 HbA1c 降低幅度相似，但使用达帕格列净而非西他列汀治疗 24 周后，体重 (BW)（p = .012）、CAP（p = .015 ）和 LS（p = .011）均有显著改善：达帕格列净治疗参与者的血清 TSP2 水平较基线明显降低（p = .035），而西他列汀治疗参与者的血清 TSP2 水平无明显变化。在相关性分析中，血清TSP2水平的变化仅与LS的变化呈正相关（r = .487，p = .006），而与达帕格列净治疗后体重、CAP或HbA1c的变化无关：结论：达帕格列净治疗后，血清TSP2水平随LS的降低而降低，且与体重、血糖控制和肝脂肪变性的改善无关，这进一步支持了血清TSP2水平作为2型糖尿病肝纤维化生物标记物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endocrinology 医学-内分泌学与代谢

CiteScore

6.40

自引率

3.10%

发文量

192

审稿时长

1 months

期刊介绍： Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.